Class / Patent application number | Description | Number of patent applications / Date published |
530329000 | 6 to 7 amino acid residues in defined sequence | 44 |
20080221304 | NOCICEPTIN-BASED ANALGESICS - The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents. | 09-11-2008 |
20080242837 | Peptide compositions - Described are treatments of disease wherein a gene-regulatory peptide as provided herein is useful as a modulator of NF-kappaB. Also described is a pharmaceutical composition for topical application comprising a gene-regulatory peptide or functional analogue thereof, wherein the peptide or analogue modulates translocation and/or activity of a gene transcription factor. | 10-02-2008 |
20080319165 | Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least one neuropeptide - The invention concerns a nucleic acid molecule which includes a nucleic acid sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide, as well as a host cell which contains this nucleic acid molecule. In addition the invention concerns a polypeptide molecule which functions as chemokine or neuropeptide or contains at least one neuropeptide, as well as fragments thereof which include at least one neuropeptide, and a procedure for the manufacture of the polypeptide molecule or of a fragment thereof. In addition the invention concerns antibodies, demonstration procedures and test-kits as well as pharmaceutical preparations. | 12-25-2008 |
20090069536 | Amide Forming Chemical Ligation - An amide is formed by reacting an α-ketoacid or salt thereof in a decarboxylative condensation reaction with an amine or salt thereof comprising a nitrogen covalently bound to an atom selected from oxygen, nitrogen, and sulfur. The amide bond is formed between the α-carbon of the ketoacid and the nitrogen of the amine. The α-ketoacid can be formed using a novel sulfur reagent. | 03-12-2009 |
20090163696 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES - Method for preparing cyclic depsipeptides having the following formula (I) | 06-25-2009 |
20090240029 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one heterocycle, aldol-based, dicarbonyl, and/or diamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one heterocycle, aldol-based, dicarbonyl, and/or diamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses. | 09-24-2009 |
20090240030 | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry - This invention provides methods for covalently affixing a biomolecule to either a second molecule or a solid surface using 1,3-dipolar cycloaddition chemistry. This invention also provides related methods and compositions. | 09-24-2009 |
20090318667 | Peptoid compositions and methods of using the same - Novel peptoids are disclosed that have a formula represented by the following formulae Ia and Ib: | 12-24-2009 |
20100222550 | Compstatin analogs with improved activity - Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed. | 09-02-2010 |
20110021748 | Non-Natural Peptides as Models for the Development of Antibiotics - Described herein are methods of screening one of the RNA hairpins in the small ribosomal subunit of bacteria to identify peptides that bind to it. The RNA hairpin target may be the 970 loop (aka helix 31 (h31)) or a modified version thereof. The identified peptides may inhibit protein synthesis and, therefore, may be used as a model for new antibiotics. | 01-27-2011 |
20110060125 | INDOLESULFONYL PROTECTING GROUPS FOR PROTECTION OF GUANIDINO AND AMINO GROUPS - The invention relates to indolesulfonyl halogenides which are useful for the protection of organic compounds comprising at least one guanidino moiety and/or at least one amino group. The invention further relates to a process for their preparation and their use as protecting reagents. The invention also relates to the process for the protecting reaction and to the protected compounds thereof. | 03-10-2011 |
20110092672 | NANOPARTICLE AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT - A nanoparticle contains a core including superparamagnetic nanoparticles and having an outer surface, and siloxanyl moieties covalently coupled to the outer surface of the core and having Formula (I): | 04-21-2011 |
20110092673 | Isolated Antibodies Against Biologically Active Leptin-Related Peptides - The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass. | 04-21-2011 |
20110213124 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS - Methods and systems to generate 6-amino-6-deoxy- | 09-01-2011 |
20120016103 | PEPSTATIN A DERIVATIVES - The invention relates to a compound having a structure according to the general formula P3-P2-P1-P1′-P2′ (I), wherein residues P3, P2, P1, P1′ and P2′ are specifically defined and may be, e.g., certain amino acid residues. The invention further relates to the use of said compound and to a method for synthesizing a peptide. | 01-19-2012 |
20120178904 | PEPTIDE ANALOGS THAT ARE POTENT AND SELECTIVE FOR HUMAN NEUROTENSIN RECEPTOR SUBTYPE 2 - Neurotensin analogs selective for neurotensin receptor subtype 2 are described. These include hexapeptides (NT(8-13)) and pentapeptides (NT(9-13)) having a D-3,1-naphthyl-alanine, D-3,2-naphthyl-alanine, an alanine derivative such as cyclohexylalanine, or 1,2,3,4-tetrahydroisoquinoline at position 11. Methods of treating pain by administering these neurotensin analogs are also described. | 07-12-2012 |
20120202969 | COMPOUND, PHOSPHORYLATION INHIBITOR, INSULIN RESISTANCE IMPROVING AGENT, PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, AND SCREENING METHOD - A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes. | 08-09-2012 |
20120253010 | COMPOUND ACCUMULATING IN INFLAMMATORY SITE, DIAGNOSTIC AGENT CONTAINING THE COMPOUND IN LABELED STATE AND ITS PRECURSOR COMPOUND FOR LABELING - Embodiments of the invention provide a compound accumulating in an inflammatory site, a diagnostic agent containing the compound in labeled state and its precursor compound for labeling. Such a compound accumulating in inflammatory site may be represented by the following formula (1): | 10-04-2012 |
20120309937 | PEPTIDES IMPARTING CELL PERMEABILITY TO LIPID MEMBRANE STRUCTURE AND/OR ENHANCING CELL PERMEABILITY OF LIPID MEMBRANE STRUCTURE, AND LIPID MEMBRANE STRUCTURE COMPRISING LIPID BOUND TO SUCH PEPTIDE AS CONSTITUENT LIPID AND HAVING CELL PERMEABILITY OR SHOWING ENHANCED CELL PERMEABILITY - Provided are peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure, and a lipid membrane structure which comprises, as a constituent lipid, a lipid bound to such a peptide and has cell permeability or shows enhanced cell permeability. The amino acid sequences of the peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure are represented by: LX | 12-06-2012 |
20130060005 | COMPOSITIONS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN CFTR AND CAL - The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface. | 03-07-2013 |
20130123464 | CEACAM BASED ANTIBACTERIAL AGENTS - Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host. | 05-16-2013 |
20130123465 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS - Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit. | 05-16-2013 |
20130165630 | AROMATIC COMPOUNDS WITH SULFUR CONTAINING LIGANDS - Compounds useful as nutritional supplements, antioxidants, heavy metal chelators and/or as intermediates for producing other related compounds with like uses have a formula: | 06-27-2013 |
20130345395 | SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS - The present invention relates to methods of preparing β-turn cyclic peptidomimetic compounds and intermediates thereof. Particularly, the present invention relates to a process for the synthesis of β-turn cyclic peptidomimetic compounds of formula I: | 12-26-2013 |
20140058063 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES - The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described. | 02-27-2014 |
20140058064 | MULTI-DRUG LIGAND CONJUGATES - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers. | 02-27-2014 |
20140066593 | PROCESS FOR A FOLATE-TARGETED AGENT - The invention described herein pertains to an improved process for preparing the folate-targeted conjugate EC145 and to the conjugate EC145 prepared using the improved process, as well as to a pharmaceutical composition comprising the conjugate EC145 prepared using the improved process. | 03-06-2014 |
20140107316 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING - Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids. | 04-17-2014 |
20140163203 | PROCESS FOR PREPARING EPTIFIBATIDE - The present invention provides processes for preparation of eptifibatide that involve coupling of amino acids in a (2+5), (4+3) and (3+4) sequence method. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide. | 06-12-2014 |
20140171619 | PEPTIDE-CROSSLINKED BIOACTIVE POLYMERIC MATERIALS - A method for creating a peptide crosslinked bioactive polymeric material includes reacting a hydroxy-functionalized small molecule with a amino acid to form an amino acid functionalized monomer, reacting the amino acid functionalized monomer with a urea bond former to form a amino acid-based poly(ester urea), and reacting the amino acid-based poly(ester urea) with a peptide based crosslinker to form the peptide crosslinked bioactive polymeric material. | 06-19-2014 |
20140221611 | BINDING MOLECULES FOR HUMAN FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure. | 08-07-2014 |
20140221612 | Peptides that Selectively Home to Heart Vasculature and Related Conjugates and Methods - The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof. | 08-07-2014 |
20140309401 | DPP-4 INHIBITOR - A DPP-4 inhibitor comprising a peptide represented by the formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe is an amino acid residue with an isoelectric point of 5.9 to 6.3; Pro/Ala/Hyp represents Pro, Ala, or Hyp; Xa is an amino acid residue other than Hyp, Pro, and Arg, or deletion; Xb is Gly, Pro, or deletion; Xc is Pro, Ala, or deletion; and Xd is an amino acid residue or deletion) as an active component. The inhibitor can be expected to bring out an effect of lowering blood glucose levels by enhancing effects of incretins; and the inhibitor may be used as a therapeutic agent for diabetes and, in addition, can act on the immune system or the like to be thus used in treatment for skin diseases or the like. | 10-16-2014 |
20140371422 | METHODS FOR MANUFACTURING AN ANTIFUNGAL AGENT - The present invention relates to an improved process for the preparation of Micafungin. | 12-18-2014 |
20140371423 | METHOD FOR PURIFICATION OF MICAFUNGIN - The present invention relates to a method for the purification of Micafungin. | 12-18-2014 |
20150148523 | GAMMA AMINO ACID BUILDING BLOCKS - The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained α-substituted-γ-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). | 05-28-2015 |
20150315253 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY, YDYNLY, FDYNFY, FDYNLY, FDYNWY, YDWNLY, YDWHLY and WDYNLY, extracted from organisms such as aquatic organisms and mossor any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 11-05-2015 |
20150320879 | SELF-STABILIZING LINKER CONJUGATES - The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component. | 11-12-2015 |
20160022831 | Peptides that Selectively Home to Heart Vasculature and Related Conjugates and Methods - The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof. | 01-28-2016 |
20160024150 | AN EPITOPE AND ITS USE - An isolated protein containing a common epitope recognized by umbilical blood antibodies specific against enterobacteria, occurring in an extract of bacterial outer membrane proteins, and fragments thereof containing said common epitope, which can be used in medicine and pharmaceutics, particularly in the production of vaccines and diagnostic tests as well as affinity materials. | 01-28-2016 |
20160145305 | ENERGY TRANSFER WITHIN PI-CONJUGATED PEPTIDE HETEROSTRUCTURES IN AQUEOUS ENVIRONMENTS - Nanostructures comprising Π-conjugated peptides for energy migration in aqueous environments are disclosed. Conductive material comprising these nanostructures, and supramolecular assemblies comprising covalently-bound electron donor-acceptor chromophores for photoinduced electron transfer also are disclosed. | 05-26-2016 |
20160158375 | DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration. | 06-09-2016 |
20160159859 | PROTEASE-RESISTANT PEPTIDE LIGANDS - This invention relates generally to the discovery of novel protease-resistant peptide ligands and uses thereof. Specifically, the present invention provides a protease-resistant peptide with three to twenty amino acids capable of binding a biological and comprising one or more basic amino acid(s) and I or aromatic amino acids, wherein one or more of the amino acids is substituted with a non-naturally occurring amino acid analog. | 06-09-2016 |
20160376310 | PEPTIDE DOMAINS THAT BIND SMALL MOLECULES OF INDUSTRIAL SIGNIFICANCE - Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, β carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or CBD that bind other ligands and can be used to immobilize the target binding domain on a support. One class of fusion proteins that is useful in industrial settings are fusions that contain concatemers of target binding domains, which increases the binding equivalents per molecule. | 12-29-2016 |